Compare Twist Bioscience Corp (TWST) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Xcel Energy Inc — how do they compare? Twist Bioscience Corp trades at $161.72 (market cap $10.08B), while Xcel Energy Inc trades at $73.64 (market cap $45.82B). The key difference: Xcel Energy Inc is far larger — about 4.5× Twist Bioscience Corp's market cap, and Xcel Energy Inc pays a 3.23% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Xcel Energy Inc for 61 Days on average.
| TWST | XEL | |
|---|---|---|
Market Cap | $10.08B | $45.82B |
Volume | 4,229,037 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $205.00 | $83.91 |
52-Week Low | $25.45 | $69.39 |
Typical Hold Time | 27 Days | 61 Days |
Enterprise Value | $10.01B | $84.14B |
Dividend Yield | — | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $162.43, up 4.36% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with RSI at 29.02 indicating potential oversold conditions. Fundamentally, revenue growth continues (2025: $377M, 2026: $432M projected) but profitability remains elusive with negative margins. Recent partnership with Eli Lilly's TuneLab platform highlights strategic positioning in AI-driven drug discovery.
While analyst consensus favors Buy (73%), the stock trades above the $145.20 target, suggesting limited near-term upside. Key risks include persistent cash burn (-$44M net CF in 2025) and high valuation multiples (P/S: 21.5). The AI biotech partnership provides growth catalyst potential, but profitability timeline remains uncertain for investors.
Xcel Energy (XEL) trades at $73.46, up 1.44% today, with a bullish technical signal and consensus analyst target of $90.83 suggesting 24% upside. Recent earnings show mixed beats, with Q2 2026 EPS of $0.93 exceeding expectations. The company maintains solid profitability with a 15.28% net margin and benefits from rising data center power demand, though it faces capital expenditure pressures with a $60 billion investment plan.
The outlook is positive, driven by infrastructure investments and load growth, but risks include high debt levels, wildfire liabilities, and interest rate sensitivity. Wall Street sentiment is bullish with 63% buy ratings, but valuation concerns persist with a P/E of 20.1 above some peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
